Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Sponsor
Jinnah Hospital
Study ID
NCT06278402
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.

Study Details

To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan. Efficacy of treatment in patients presenting with alopecia areata will be assessed using SALT Score on follow up at 6,12 and 24 weeks where four categories of treatment response were defined: 0 (re-growth ≤10%), 1 (11-25%), 2 (26-50%), 3 (51-75%) and 4 (re-growth \>75%). Efficacy will be considered if re-growth ≥ 2.

Key Dates

Start date
Jul 1, 2023
Status verified
Feb 2024
Primary completion
Jan 6, 2024
Completion
Jan 16, 2024

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib
    tofacitinib 5mg twice daily for 6 months

Primary Outcome Measure

Alopecia [ Time Frame: 6 months ]

Related Studies